- Industry Veteran Joins Company as Lead Product Progresses in Phase 2
SAN FRANCISCO, Jan. 16 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, M.D. has joined VIA as senior vice president of research and development. Dr. Taub brings extensive experience as a pharmaceutical executive heading up major development programs in metabolic diseases as well as more than 15 years as a principal investigator at major academic medical centers.
"Becky will be able to make immediate contributions to VIA. She will play a critical role in defining and implementing the overall strategy at VIA and we are thrilled to have someone with her breadth of experience join our senior management team," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "Becky, along with our strong existing team, will contribute to the clinical and commercial development of our lead product candidate VIA-2291, which is in multiple Phase 2 trials investigating its potential to treat vascular inflammation. In addition, she will work in developing strategies for establishing rapid and convincing proof-of-concept clinical studies for additional product candidates, including helping us assess the potential of products currently in our pre-clinical pipeline. Studies show there is a strong link between metabolic diseases and cardiovascular diseases, and we believe that Becky's background and experiences are ideally suited to VIA."
Dr. Taub joins VIA from Roche Pharmaceuticals, a unit of Roche Holding
Ltd., where she has served as vice presi
|SOURCE VIA Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved